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Abstract 
Non-medullary thyroid carcinoma is an entity mostly recognized as sporadic and non-
aggressive. Although the definition of its familial form (FNMTC) is still controversial, it has 
increasingly been identified by epidemiologic studies that suggest a more aggressive behavior 
and worse prognosis than the sporadic counterpart. Recent studies have identified six 
susceptibility loci that may be responsible for FNMTC inheritance. We intend to contribute to 
the increasing evidence that justify the investment on a more close surveillance and follow-up 
of members of affected families. Reachable members of a previously identified family with 
FNMTC were clinically evaluated by thyroid palpation, thyroid ultrasound and thyroid blood 
tests. Blood samples were drawn for genotyping. From eight NMTC cases in this family, 2 were 
diagnosed before the commencement of the family screening, 5 during the screening and 1 
during this evaluation. However, these cases did not present with characteristics of 
aggressiveness. In addition, various benign thyroid disorders were also identified. Linkage 
analysis excluded MNG1 and TCO as susceptibility loci in this family. The high incidence of 
cases in these kindreds and the aggressiveness that these tumors may present justify the 
recommendation for a closer follow-up and more intensive treatment approach. 
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Introduction 
hyroid carcinomas are an extremely important clinical entity. Over the last three decades 
its incidence has increased more than twofold in the United States, with similar patterns 
of increase reported all over the world, which may be due to a real incidence 
augmentation or to increased medical surveillance and more sensitive diagnostic tests.[1, 2] 
Although it presents a modest prevalence (~1% of human malignancies) and a generally good 
prognosis and non-aggressive behavior, its revision is embedded with a special significance: it 
is a magnificent oncogenesis model which may help to bring light to the study of a wide variety 
of carcinomas.   Almost 95% of patients have well-differentiated cancer of follicular cell origin, 
including papillary carcinoma and its variants (80-90%) and follicular carcinoma(10-15%).[3] 
Undifferentiated neoplasms, like anaplastic carcinoma, account for minimal percentage of 
cases. Usually, these kind of neoplasm are taken as sporadic, unlike medullary thyroid cancer 
(neoplasm arising from the calcitonin-producing C cells), which account for 5% of thyroid 
cancers. Twenty percent of these patients have a well established familial occurrence as part 
of the multiple endocrine neoplasia type 2 (MEN-2) or in a familial form without neoplasia of 
other tissues (MTC-only syndrome).[4]  
T 
The occurrence of non-medullary thyroid cancers (NMTC) is traditionally considered to 
be sporadic and associated with radiation exposure but recently, data from epidemiologic 
studies has brought to light the evidence of a familial form of NMTC (FNMTC). In fact, several 
multiple-hit familial clusters, non-exposed to environmental risk factors, brought the need for 
testing these families genetic background. FNMTC accounts for approximately 5% of all thyroid 
cancers of follicular cell origin, ranging from 2,5% to 10,5%. [5, 6] 
Carcinoma of thyroid follicular cells in a familial setting was first described in 1955, in 
identical 24-years-old twins. [7] Recently, Fallah et al. estimated the lifetime cumulative risk of 
thyroid cancer (CRTC) in first-degree relatives of patients with papillary thyroid carcinoma 
(PTC) to be 2% in females (1% in males), representing a threefold increase over the general 
population risk. When there were more than 2 PTC patients diagnosed at age <60 years in a 
family, the CRTC increased to 10% in females (24% in males). [8] This underlines the issue 
regarding the definition of FNMTC. In 2000, Musholt et al. created a series of clinical criteria 
for the diagnosis of FNMTC based on its associations with benign thyroid disease, and its 
clinical and aggressiveness characteristic.[9] Still, these criteria did not reach a general 
acceptance. Most recent reports establish the presence of FNMTC in kindreds with 2 affected 
members. However, Charkes’ work state that in 2-hit families, 62%–69% of affected members 
are sporadic cases. In families having 3 or more affected members, more than 96% would have 
the familial trait.[10] Therefore, although still controversial, recent studies assume the real 
definition for FNMTC as being the presence of NMTC in 3 or more family members, in the 
absence of other known associated syndromes or exposure to environmental factors known to 
cause thyroid cancer.    
FNMTC encompass a heterogeneous set of diseases and is divided into two groups. 
The first includes familial syndromes characterized by predominance of non-thyroidal tumors 
and associated with higher risk of NMTC (Table 1), such as familial adenomatous polyposis 
(FAP), PTEN hamartoma tumor syndrome (PHTS), Carney complex type 1 and Werner 
syndrome.  
 
Table 1| Hereditary tumor syndromes associated with thyroid cancer. 
Disorder Chromosomal 
location 
Gene Inheritance Thyroid pathology 
PHTS 10q22-23 PTEN AD FTC (5-10%); 
MNG, MAN, FA, PTC (50-
67%) 
FAP 5q21 APC AD PTC (cribiform pattern) 
Carney complex 2p15-15, 
17q22-24 
PRKAR1a AD PTC, FTC (15%) 
Werner syndrome 8p11-21 WRN AR PTC, FTC, ATC 
MEN1 11q13 MEN1 AD Rare 
MEN2A 10q11.2 RET AD Micro PTC 
McCune Albright 
syndrome 
20q13.1-13.2 GNAS1 Mosaic FA, FTC 
Abbreviations: PHTS – PTEN hamartoma tumor syndrome; FAP – Familial adenomatous polyposis; MEN – multiple endocrine neoplasia; AD – autosomal dominant; AR – 
autosomal recessive; FTC – Follicular thyroid carcinoma; MNG – multinodular goiter; MAN – multiple adenomatous nodules; FA – follicular adenoma; PTC – papillary thyroid 
carcinoma; ATC – anaplastic thyroid carcinoma.[11] 
 
 
The second includes familial syndromes characterized by predominance of NMTC 
(Table 2). The focus of this report is on this second group. FNMTC is 2 to 3 times more common 
in women than men, as is sporadic PTC, and presents with an increased incidence of benign 
thyroid neoplasia. [12] The pathological subtype is more frequently PTC, although cases of 
familial follicular thyroid carcinoma have been described.  
The genetic inheritance of FNMTC remains unknown and no susceptibility genes have 
yet been identified. Therefore, it remains to be definitively proven that FNMTC is a classical 
familial tumor syndrome. Several reports postulated an autosomal dominant way of 
inheritance, with incomplete penetrance and variable expressivity. Six potential regions for 
harboring an FNMTC gene have been pointed out as targets: MNG1 (14q23), thyroid 
carcinoma with oxyphilia (TCO; 19p13.2), fPTC/PRN (PRN; 1q21), NMTC (2q21), FTEN (8p23.1-
p22), and telomere-telomerase complex. 
 
Table 2| Familial tumor syndromes characterized by predominance of NMTC 
Abbreviations: PTC – papillary thyroid carcinoma; PRN – papillary renal neoplasia; BTN – benign thyroid nodules; MNG – multinodular goiter; FPTC – familial papillary thyroid 
cancer; TCO – thyroid carcinoma with oxyphilia; AD – autosomal dominant.[11] 
 
There are still important difficulties regarding the diagnosis of FNMTC. Because of the 
inability to genetically test for this condition, the diagnosis is based solely on family history. 
The identification of the susceptibility genes responsible for FNMTC would make screening and 
early diagnosis much easier, contributing for improved survival and disease-free rates. 
Although still controversial, the strength of the current epidemiologic data underlines the 
importance of considering this a special entity that justify the investment on a more close 
surveillance and follow-up of members of affected families. Our study presents one identified 
8-hits, four generations Portuguese family with FNMTC and its clinical follow-up during a 10-
years period. We also formulate an attempt on the genetic analysis of the affected members of 
the family by studying MNG1 (14q32) and TCO (19p13.2) as possible susceptibility loci.  
 
Methods 
Family 
Based on the previous identification of this multiple-hit portuguese family by Costa, E. 
(“Carcinoma não-medular familiar da glândula tireóide – Identificação e caracterização de 
agregados familiares”), we collected the clinical data from all the reachable family members. 
The trial was approved by the Ethics Committee of Centro Hospitalar de São João, E.P.E..  
Informed consent was obtained from all the enrolled subjects. We have not examined 
members of the family who were under the age of 5 years old. Where available, the results of 
isotope imaging, ultrasound and histopathology of tissue from surgery have been reviewed. 
The subjects were reviewed regarding previous medical history and screened with thyroid 
palpation, thyroid ultrasound and thyroid blood tests. When indicated by the results of the 
previous tests, fine-needle biopsy aspiration and/or thyroid scintigraphy were performed. 
Blood samples were drawn for genotyping. 
 
DNA extraction and Microsatellite markers genotyping 
Blood samples were collected from seven affected persons [five with PTC (A, B, J, M 
and N) and two with benign lesions (L and O) and from one unaffected person (III-3)], after 
Disorder Chromosomal 
location 
Candidate 
Genes 
Inheritance Tissue Pathology 
PTC associated with PRN 
(fPTC/PRN) 
1q21 Unknown Unknown PTC, BTN, PRN 
Familial MNG with PTC 14q31 Unknown AD MNG, PTC 
FPTC 2q21 Unknown Unknown PTC 
Familial TCO and without 
oxyphilia 
19p13.2 Unknown/ 
TCO/ 
TIMM44 
AD PTC with/without 
oxyphilia 
their informed consent was obtained. Genomic DNAs were extracted according to a standard 
phenol-chloroform protocol. The eight samples were genotyped with fluorescently labelled 
microsatellite markers of chromosomes 14 (D14S74, D14S1030 and D14S611) and 19 
(D19S413, D19S586 and D19S407), from Invitrogen™.  
Each PCR reaction included 1 X PCR buffer, 1.5 mM MgCl2, 200 mM of each dNTP, 100 
ng DNA, 0.2 U Red Hot DNA polymerase (Advanced Biotechnologies), and 5 pmol of each 
primer (one of them fluorescently labeled) in a 10-μl final reaction volume. Thermocycling 
conditions, using a GeneAmp PCR system 9700 thermocycler (Applied Biosystems, Foster City, 
CA, USA) were: 94ºC for 10 min; 30 cycles of 94ºC for 30 s, 55ºC [markers (D14S74, D14S1030, 
D19S586)] or 58ºC [markers (D14S611, D19S413, D19S407)] for 30 s, and 72ºC for 30 s; and 
final extension at 72ºC for 5 min. Separation and detection were performed using the ABI 
PRISM 3100 Genetic Analyser 16-capillary electrophoresis system. To each PCR product, 9.5 μl 
of HiDi formamide (Applied Biosystems) and 1.5 μl of internal size standard GS500 LIZ (Applied 
Biosystems) were added. Fragment sizes were automatically determined using GeneScan 
Analysis 2.1. 
 
Results 
A pedigree chart of the family, referring to the commencement of the screening, is 
displayed in Figure 1. The pedigree chart referring to the present situation is displayed in 
Figure 2. In this kindred there were 61 members that would fall onto the inclusion criteria, but 
we were able to contact and study only 37 (59%). The prevalence of PTC was 21,6%. Eight 
members of the family presented with papillary thyroid carcinoma (PTC),  2 with thyroid 
nodule, 5 with multinodular goiter (MNG) and 2 with thyroiditis.  The mode of inheritance 
suggests autosomal dominancy with incomplete penetrance, and women seem to be affected 
more frequently than men. The pathological characteristics and treatment of the 8 PTC cases 
are summarized on Table 3.  
From the initial evaluation of this family, in 2003, by Costa, E., 4 new cases of PTC were 
identified (A, P, Q and R), all of them in previously affected patients:  three patients with 
thyroid nodules and one with MNG (A). The patient A was initially diagnosed with follicular 
adenoma and treated with chirurgical enucleation of benign nodule in 1985; MNG was 
diagnosed at 43 years of age and PTC developed at the age of 67, on family screening. Patient 
P was diagnosed with a multifocal and bilateral PTC at the age of 28, but we were unable to 
screen him by the time of the present report. Patients Q and R had initially been diagnosed 
with benign cystic nodules of 10 and 6 mm of diameter, respectively; patient Q developed PTC 
at the age of 30 and patient Q at the age of 34, both of them detected in the context of family 
screening (patient R at this evaluation). Also, the 2 siblings previously diagnosed with PTC (M 
and N) had been identified independently without knowledge of positive family history, both 
at the age 32; patient N was diagnosed with relapse by thyroid scintigraphy, during this follow-
up, one year after the initial diagnosis. He was treated with central and lateral neck dissection. 
Patient B was diagnosed at the commencement of the prospective family screening with MNG 
without cytologic evidences of malignancy; subsequent total thyroidectomy due to 
compressive symptoms at the age of 61 revealed an Hurthle cell variant of PTC embedded on 
MNG. Patient J was diagnosed with MNG and multifocal bilateral PTC at the age of 41, on 
family screening.  
 
Table 3| Pathological characteristics and treatment of the PTC cases. 
Patient Age at 
diagnosis 
Ultrasonographic 
characteristics 
Thyroid 
histopathology 
Treatment 
A 67 MNG 
2 right lobe nodules (23 and 
17mm Ø) 
MNG 
PTC, classic 
variant 
Total 
thyroidectomy 
B 61 MNG 
1 right lobe nodule (30 mm 
Ø) 
1 left lobe nodule (26mm Ø) 
MNG 
Hurthle  cell 
variant of PTC 
Total 
thyroidectomy 
J 41 MNG 
2 right lobe nodules (18 and 
16mm Ø) 
MNG 
Multifocal, non-
capsulated, 
classic variant 
PTC 
Total 
thyroidectomy 
+ I
131
 therapy 
M 32 Thyroid nodule (18mm Ø) PTC, classic 
variant 
Total 
thyroidectomy  
N 32 Thyroid nodule (13mm Ø) PTC, classic 
variant 
Total 
thyroidectomy 
+ Central and 
lateral neck 
dissection 
P 28 Thyroid nodule (15mm Ø) Encapsulated PTC Total 
thyroidectomy 
Q 30 Right lobe solitary nodule 
(14mm Ø) 
Non-capsulated, 
classic variant 
PTC 
Total 
thyroidectomy 
R 
 
34 MNG 
Predominant right lobe 
nodule (30mm Ø) 
NA NA 
Abbreviations: NA – not available.  
 
Patients C and D were diagnosed with thyroid nodule and MNG at the age of 49 and 
46, respectively; both feature with benign cytologic and ultrasonographic characteristics. The 
five siblings E to I all presented with thyroid pathology at the commencement of family 
screening; the results of FNBA were all consistent with benign findings (cystic and colloid 
nodules). Patient L was diagnosed at the age of 31 with MNG and at 35 with Hashimoto’s 
thyroiditis/hypothyroidism with high titers of autoantibodies (anti-thyroid peroxidase of 28,51 
UI/ml), subsequently treated with thyroxine. Patient O was diagnosed with hypothyroidism 
after her last pregnancy and presents with ultrasonographic characteristics of thyroiditis. 
 
Linkage analysis 
 
We verified that affected and non-affected members shared the same haplotype (data 
not shown), therefore excluding linkage to the aforementioned susceptibility loci (TCO and 
MNG1). The limit of detection (LOD) score for this family was not calculated because there 
were few members and markers. 
  
Discussion 
In this report we describe a Portuguese family with 8 cases of PTC associated with 
thyroid nodules (2 cases), MNG (5 cases) and thyroiditis (2 cases).  
There are well-knonw risk factors to develop PTC, namely exposure to radiation, 
deficient or excessive iodine intake, TSH levels, autoimmune thyroiditis, obesity and 
environmental polluents. [13] Low iodine intake causing high prevalence of endemic goiter 
have remained for many years the most important risk factor for follicular carcinoma. Iodine
Figure 1| Pedigree chart of the family studied - 2003 
 
 
63 
43 
48 46 37 ? 
59 
61 
61 ? 69 67 61 
71 46 
Ukn Unk AMI 
Unk Unk 
 
46 42 41 28 ? 2 ? ? ? 33 31 36 32 30 25 28 25 24 20 16 
29 15 20 13 22 
31 22 
14 
? ? 23 2 10 7 
12 7 5 1 
15 2 
6 
46 48 46 42 41 28  31 32 32 
30 
35 
34 
Figure 1| Pedigree chart of the family studied – 2013 
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intake is known to influence the thyroid cancer histotype distribution, rather than the overall 
incidence, with more follicular and fewer papillary carcinomas in iodine-deficient areas. When 
iodine prophylaxis was introduced the papillary/follicular ratio increased. The gender-ratio 
distribution has also been modified by introduction of iodine enriched salt in 1971 in Portugal, 
with female patients being more affected. This could partly explain the preponderance of PTC 
and female cases in this family, but not the high incidence within the family. The majority of 
the family members described here live in the North coastal zone of the country, an area with 
no endemic goiter and low incidence of environmental iodine deficiency or excess. Therefore, 
the proportion of family members with MNG or PTC in this kindred is considered to be too high 
to be explained by iodine influence. Also, there is no indication that any member of the family 
had been exposed to ionizing radiation. There are several members that present with MNG or 
PTC at very early age, thus suggesting a genetic predisposition rather than exposure to 
environmental risk factors.  
One of the most controversial issues regarding FNMTC is whether it presents with a 
more aggressive behavior and a worse prognosis than sporadic neoplasias. Most studies 
advocate that FNMTC has a predisposition to characteristics that attest tumor aggressiveness 
such as younger age at presentation, multifocality, bilaterality, local invasion, extrathyroidal 
invasion, lymph node metastases, and high recurrence rates. [12, 14-18] FNMTC patients have 
shorter disease-free survival than do sporadic disease patients,[9, 10, 12, 14, 19, 20] and 
Uchino et al. and Alsanea et al. even consider it an independent predictor of shorter disease-
free survival.[12, 14] Recently, Mazeh et al. even postulated that patients with NMTC having a 
family history of thyroid cancer have more aggressive disease, regardless of whether they 
meet the current deﬁnition of FNMTC regarding number of affected family members.[21] 
However, some studies fail to recognize any significant difference between familial and 
sporadic tumor’s characteristics or survival rates.[22-25] In this study, from 8 FPTC cases, 1 was 
histopathologically described as multifocal and 2 as non-capsulated, locally infiltrative 
carcinomas. One case (patient N) relapsed during the follow-up. The majority of the cases, 
however, did not present the aggressive characteristics commonly associated with FPTC. 
Recent studies have also underline the issue of clinical anticipation: compared with their 
parents, patients in the second generation had younger age at diagnosis, after ruling out the 
bias of screening effect, greater multicentricity and bilaterality, higher metastasis rate and 
worst prognosis.[16, 17] This effect is concordant with our findings, namely, the median age of 
diagnosis in the second generation was 29 years younger than the first generation.  
As the genetic causes of most cases of FNMTC remain unknown, widespread genetic 
testing is not available. We performed linkage analysis of two of the susceptibility loci 
previously identified: MNG1 (14q32) and TCO (19p13.2). We did not find any association with 
the 2 aforementioned loci. Our data suggest that these two candidate regions are not 
frequently involved in Portuguese FNMTC. Since the linkage analysis in this informative family 
showed no evidence for the involvement of any of the two candidate regions, we decided to 
perform a subsequent Whole-Genome Association Study in an attempt to find new loci 
predisposing to FNMTC. This study is utilizing the Affymetrix® Genome-Wide Human SNP Array 
6.0, that features 1.8 million genetic markers, including more than 906,600 single nucleotide 
polymorphisms (SNPs) and more than 946,000 probes for the detection of copy number 
variations (data not available). 
Considering the relative higher aggressiveness of FNMTC compared with its sporadic 
counterpart, the screening, management and treatment of the members of these families 
constitute a challenge. Most authors advocate that all members of affected families should 
undergo a careful history and thorough physical examination, followed by ultrasonography of 
the thyroid gland and cervical lymph nodes. This would warrant early detection of smaller, 
earlier stage tumors which probably improves clinical outcome. In our study, 6 of the 8 FPTC 
cases were diagnosed on family screening, both in previously affected and non-affected 
patients, re-enforcing the importance for systematically screen these patients. Most case 
reports/series ﬁnd the mean age of diagnosis for patients with FNMTC to be similar to those 
with sporadic NMTC,[1, 12, 25] but there are some that have noted a slightly earlier 
presentation, as occurs in most familial syndromes.[9, 14, 19] A meta-analysis found that 
patients with FNMTC presented up to a decade earlier than their sporadic counterparts, with a 
peak age of onset in FNMTC patients of the fourth decade. [5] Therefore, we would advice that 
the commencement of screening was done 5 to 10 before the youngest age of onset, for most 
families around age 20, with a regular yearly follow-up if screening history, physical 
examination, and ultrasound are negative. [26] Fine-needle aspiration (FNA) is an important 
part of the diagnostic evaluation of a thyroid nodule. However, FNA has been shown to be less 
reliable in patients with FNMTC, due to the higher incidence of multifocality, bilaterality and 
multiple benign nodules. [1] Taking into account the aforementioned aggressiveness of these 
tumors, we recommend a prophylactic total thyroidectomy in any patient with a thyroid 
nodule and a strong family history, regardless of the FNA result, as do many other authors. 
This recommendation is supported by the fact that many of the FPTC develop in previously 
affected patients with benign thyroid nodules by FNA, as seen in this family. This somehow 
aggressive approach has important advantages: 1) it allows the use of radioactive iodine 
ablation to treat and scan patients; 2) it provides serum thyroglobulin as a sensitive tumor 
marker post-operativly; 3) it may improve prognosis of these patients as it provides an earlier 
treatment, before the tumor is clinical, radiological or cytologically apparent.     
All patients with biopsy-proven FNMTC should undergo total thyroidectomy. As all 
thyroid tissue has similar genetic predisposition to develop malignancy, residual tissue should 
be avoided whenever possible. Due to the high lymph node involvement, prophylactic central 
neck dissection and postoperative radioactive iodine ablation followed by thyroid hormone 
suppression should be considered because of the elevated recurrence rate and mortality 
associated with recurrence rate. The optimal follow-up for patients with a diagnosis of FNMTC 
is unknown, but it would be, at very least, the standard of care for their stage of disease, if not 
closer. 
 
Conclusion 
 
 The kindred studied represent a good example of FNMTC cases. Our report supports 
the idea that a close follow-up and surveillance of these families constitutes a way of 
improving the precocity of diagnoses, and thereby, the prognosis of these patients. An 
aggressive treatment approach seems to be beneficial, since papillary carcinoma was found 
even on a patient operated with an initial diagnosis of benign MNG. The demographic 
characteristics of this kindred and the new genetic approach now used may provide clues for 
the final understanding of this entity.  
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